Consensus Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
28.6 USD -0.35% Intraday chart for Arrowhead Pharmaceuticals, Inc. +1.31% -6.54%

Evolution of the average Target Price on Arrowhead Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e5a386ccf9e2e2b4e05.8mclzsmCY9JpndVj6zZ0C0PxFROe8f794QbKDdqWeLI.mwEQpJbYKJoCrKQuhn0taSTFRSXuxLbPoECAfbf8EOqcPlaAu-RbnQTFnA~c682567b0c0bfc27cf5c0868657f713b
B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating MT
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating MT
BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $50 From $60, Notes Higher Cash Burn; Keeps Buy Rating MT
Morgan Stanley Cuts Price Target on Arrowhead Pharmaceuticals to $37 From $40, Maintains Equal-Weight Rating MT
TD Cowen Starts Arrowhead Pharmaceuticals at Outperform MT
Piper Sandler Adjusts Price Target on Arrowhead Pharmaceuticals to $59 From $52, Maintains Overweight Rating MT
SVB Leerink Downgrades Arrowhead Pharmaceuticals to Market Perform From Outperform, Price Target is $40 MT
Goldman Sachs Adjusts Arrowhead Pharmaceuticals' Price Target to $73 From $65, Keeps Buy Rating MT
Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $40 From $37, Maintains Equalweight Rating MT
SVB Securities Upgrades Arrowhead Pharmaceuticals to Outperform From Market Perform, Raises PT to $35 From $21 MT
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $60 From $77, Maintains Outperform - Speculative Risk Rating MT
Bernstein Initiates Arrowhead Pharmaceuticals at Market Perform With $27 Price Target MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $55 From $59, Keeps Buy Rating MT
UBS Adjusts Arrowhead Pharmaceuticals' Price Target to $78 From $80, Maintains Buy Rating MT
Baird Trims Price Target on Arrowhead Pharmaceuticals to $58 From $60, Maintains Outperform Rating MT
RBC Capital Adjusts Price Target on Arrowhead Pharmaceuticals to $77 From $83 on Hepatitis B Virus Therapy Deprioritization, Keeps Outperform Rating MT
Piper Sandler Adjusts Arrowhead Pharmaceuticals' Price Target to $52 From $55, Maintains Overweight Rating MT
UBS Adjusts Arrowhead Pharmaceuticals Price Target to $80 From $88, Maintains Buy Rating MT
Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $60 From $82, Keeps Buy Rating MT
HC Wainwright Adjusts Arrowhead Pharmaceuticals' Price Target to $90 From $110, Keeps Buy Rating MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $59 From $65, Keeps Buy Rating MT
Goldman Sachs Adjusts Price Target on Arrowhead Pharmaceuticals to $66 From $65, Maintains Buy Rating MT
Jefferies Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $92, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Arrowhead Pharmaceuticals to $37 From $41, Maintains Equal-Weight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
28.6 USD
Average target price
55.15 USD
Spread / Average Target
+92.85%
High Price Target
90 USD
Spread / Highest target
+214.69%
Low Price Target
28 USD
Spread / Lowest Target
-2.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Arrowhead Pharmaceuticals, Inc.

B. Riley
UBS
BofA Securities
Morgan Stanley
TD Cowen
Piper Sandler
SVB Securities LLC
Goldman Sachs
RBC Capital Markets
Bernstein
Baird
Chardan Research
HC Wainwright
Jefferies & Co.
SVB Leerink
Chardan
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Arrowhead Pharmaceuticals, Inc. - Nasdaq
  4. Consensus Arrowhead Pharmaceuticals, Inc.